PRPO vs. TBIO, TLIS, AXDX, HLTH, OMIC, NCNA, EFTR, ADXN, MEDS, and OBSV
Should you be buying Precipio stock or one of its competitors? The main competitors of Precipio include Telesis Bio (TBIO), Talis Biomedical (TLIS), Accelerate Diagnostics (AXDX), Cue Health (HLTH), Singular Genomics Systems (OMIC), NuCana (NCNA), eFFECTOR Therapeutics (EFTR), Addex Therapeutics (ADXN), TRxADE HEALTH (MEDS), and ObsEva (OBSV). These companies are all part of the "medical" sector.
Telesis Bio (NASDAQ:TBIO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.
Precipio has a consensus price target of $40.00, suggesting a potential upside of 569.10%. Given Telesis Bio's higher probable upside, analysts plainly believe Precipio is more favorable than Telesis Bio.
In the previous week, Telesis Bio had 1 more articles in the media than Precipio. MarketBeat recorded 2 mentions for Telesis Bio and 1 mentions for Precipio. Precipio's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.
Precipio received 263 more outperform votes than Telesis Bio when rated by MarketBeat users. Likewise, 73.32% of users gave Precipio an outperform vote while only 52.94% of users gave Telesis Bio an outperform vote.
Precipio has a net margin of -38.51% compared to Precipio's net margin of -173.78%. Telesis Bio's return on equity of -51.75% beat Precipio's return on equity.
Telesis Bio has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
Precipio has lower revenue, but higher earnings than Telesis Bio. Precipio is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 24.5% of Telesis Bio shares are held by company insiders. Comparatively, 10.6% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Precipio beats Telesis Bio on 8 of the 15 factors compared between the two stocks.
Get Precipio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precipio Competitors List
Related Companies and Tools
